

Display Settings: Abstract

Send to:



Arch Toxicol. 2012 May;86(5):753-66. doi: 10.1007/s00204-012-0809-3. Epub 2012 Feb 18.

Casiopeina II-gly and bromo-pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation.

Marín-Hernández A, Gallardo-Pérez JC, López-Ramírez SY, García-García JD, Rodríguez-Zavala JS, Ruiz-Ramírez L, Gracia-Mora I, Zentella-Dehesa A, Sosa-Garrocho M, Macías-Silva M, Moreno-Sánchez R, Rodríguez-Enríquez S.

Departamento de Bioquímica, Instituto Nacional de Cardiología, Juan Badiano No. 1, Col. Sección XVI Tlalpan, 14080 México, DF, Mexico. marinhernandez@yahoo.com.mx

Abstract

The copper-based drug Casiopeina II-gly (CasII-gly) shows potent antineoplastic effect and diminishes mitochondrial metabolism on several human and rodent malignant tumors. To elucidate whether CasII-gly also affects glycolysis, (a) the flux through the complete pathway and the initial segment and (b) the activities of several glycolytic enzymes of AS-30D hepatocarcinoma cells were determined. CasII-gly (IC₅₀ = 0.74-6.7 μM) was more effective to inhibit 24-72 h growth of several human carcinomas than 3-bromopyruvate (3BrPyr) (IC₅₀ = 45-100 μM) with no apparent effect on normal human-proliferating lymphocytes and HUVECs. In short-term 60-min experiments, CasII-gly increased tumor cell lactate production and glycogen breakdown. CasII-gly was 1.3-21 times more potent than 3BrPyr and cisplatin to inhibit tumor HK. As CasII-gly inhibited the soluble and mitochondrial HK activities and the flux through the HK-TPI glycolytic segment, whereas PFK-1, GAPDH, PGK, PYK activities and HPI-TPI segment flux were not affected, the data suggested glycogenolysis activation induced by HK inhibition. Accordingly, glycogen-depleted as well as oligomycin-treated cancer cells became more sensitive to CasII-gly. The inhibition time-course of HK by CasII-gly was slower than that of OxPhos in AS-30D cells, indicating that glycolytic toxicity was secondary to mitochondria, the primary CasII-gly target. In long-term 24-h experiments with HeLa cells, 5 μM CasII-gly inhibited OxPhos (80%), glycolysis (40%), and HK (42%). The present data indicated that CasII-gly is an effective multisite anticancer drug simultaneously targeting mitochondria and glycolysis.

PMID: 22349057 [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

LinkOut - more resources

Save items

Add to Favorites

Related citations in PubMed

Control of cellular proliferation by modulatic [Toxicol Appl Pharmacol. 2006]

Energy metabolism in H460 lung cancer cells: effects of histone [PLoS One. 2011]

Energy metabolism transition in multi-cellular human tum [J Cell Physiol. 2008]

Review Hexokinase-2 bound to mitochondria: [Semin Cancer Biol. 2009]

Review 3-Bromopyruvate: targets and outcomes. [J Bioenerg Biomembr. 2012]

See reviews...

See all...

Cited by 1 PubMed Central article

Whole genome gene expression analysis reveals casio [PLoS One. 2013]

Related information

Related Citations

Compound

Compound (MeSH Keyword)

Substance

Substance (MeSH Keyword)

Cited in PMC

Recent activity

Turn Off Clear

Casiopeina II-gly and bromo-pyruvate inhibition of tumor PubMed

See more...

You are here: NCBI > Literature > PubMed

Write to the Help Desk

GETTING STARTED

- NCBI Education
- NCBI Help Manual
- NCBI Handbook
- Training & Tutorials

RESOURCES

- Chemicals & Bioassays
- Data & Software
- DNA & RNA
- Domains & Structures
- Genes & Expression
- Genetics & Medicine
- Genomes & Maps
- Homology
- Literature
- Proteins
- Sequence Analysis
- Taxonomy
- Training & Tutorials
- Variation

POPULAR

- PubMed
- Nucleotide
- BLAST
- PubMed Central
- Gene
- Bookshelf
- Protein
- OMIM
- Genome
- SNP
- Structure

FEATURED

- Genetic Testing Registry
- PubMed Health
- GenBank
- Reference Sequences
- Map Viewer
- Human Genome
- Mouse Genome
- Influenza Virus
- Primer-BLAST
- Sequence Read Archive

NCBI INFORMATION

- About NCBI
- Research at NCBI
- NCBI Newsletter
- NCBI FTP Site
- NCBI on Facebook
- NCBI on Twitter
- NCBI on YouTube

